Strategic Plan 2018; Financial Information. Astellas shares fell in afternoon trading after the earnings release, closing down 2% at 1,544 yen amid investor concern about a looming patent cliff. EPS: The annual earnings per share. There is no recent news for this security. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. You will enter external sites beyond here. On October 30, Astellas Pharma will release earnings for the most recent quarter. Astellas Pharma Inc (OTCPK:ALPMF) Q3 2021 Earnings Conference Call January 29, 2021 2:00 AM ET. Earnings Momentum Score Average 47.79 Login to Access: 47.79 Login to Access: Dividend Quality Score Average 100 Login to Access: Login to Access: Fundamental Score Above Average 82 Login to Access: 29.00 Login to Access: Dividend Yield (%) Average 2.31 Login to Access: 1.16 Login to Access: Next release date Get the latest Astellas Pharma Inc. ALPMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. On August 4, Astellas Pharma will present their latest quarterly figures. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Naoki Okamura – Representative Director and Executive Vice President. Latest Developments More. Royalty income makes up a small percentage of Astellas' overall sales. Get today's Astellas Pharma Inc. stock price and latest 4503 news as well as Astellas Pharma Inc. real-time stock quotes, technical analysis, full financials and more. Earnings date: N/A: Forward dividend & yield: 0.36 (2.60%) Ex-dividend date: 30 Mar 2021: 1y target est: N/A: All. Company Participants. Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy. Astellas Pharma Inc. (TSE: 4503) announced today that it had extended its all-cash tender offer for $57.50 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) to 12:00 midnight New York City time on Wednesday, June 2, 2010, unless further extended. Active Ingredients: Solifenacin succinate, Tamsulosin Hydrochloride . Diary of Japan (.N225) corporate earnings for the week ahead JAPAN EARNINGS Start Date Start RIC Company Name Event Name Time 11-May-2020 02:30 9107.T Kawasaki Kisen … Company Participants. Astellas Pharma PE ratio as of February 02, 2021 is 18.94. View the latest Astellas Pharma Inc. (ALPMF) stock price, news, historical charts, analyst ratings and financial information from WSJ. Earnings Date-Ex Div Date 09/25/2020; Div Amount 0.2011; Split Date-Split Factor-Latest Astellas Pharma Inc News. Astellas Receives … Vesomni 6 mg/0.4 mg modified release tablets. Earnings Date-Ex Div Date 09/29/2020; Div Amount 21.00; Split Date-Split Factor-Latest Astellas Pharma Inc News. Analysts on Wall Street predict Astellas Pharma will release earnings per share of ¥29.99. (1) Consolidated financial results of Yamanouchi Pharmaceutical Co., … Astellas Pharma Inc. … Last Earnings Release: N/A; Next Ex-Dividend Date: N/A; Last Ex-Dividend Date: Sep. 29, 2020; Description: Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. Get News Alerts by Email Year All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Category All Categories Corporate Corporate Awards Corporate Social Responsibility Our People Therapeutic Area News Uncategorized Keywords Go Earnings Date-Ex Div Date 09/29/2020; Div Amount 21.00; Split Date-Split Factor-Latest Astellas Pharma Inc News. It is based on a 36-month historical regression of the return on the stock onto the return on the S&P 500. Company: Astellas Pharma Co. Ltd. Astellas Pharma Inc (OTCPK:ALPMF) Q1 2021 Earnings Conference Call August 4, 2020 3:00 AM ET. (This link opens in a new window) Cancel Click here to leave this site. Astellas Pharma Inc. TEL +81-3-3244-3201 Release for the financial results of Astellas for FY2004 Japan, May 17, 2005 - Astellas Pharma Inc. today announced the financial results of former Yamanouchi Pharmaceutical Co., Ltd. and former Fujisawa Pharmaceutical Co., Ltd. for FY2004 (fiscal year ended March 31, 2005). Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Track Astellas Pharma stock price in real-time ahead here. The latest earnings, revenues and financial reports for Astellas Pharma Inc. (4503). Astellas Pharma will report earnings from the last quarter on January 29. Earnings: The amount and date of latest Earnings Per Share (EPS) paid out to shareholders. Astellas Pharma reported 21.29 in PE Price to Earnings for its fourth fiscal quarter of 2020. Q3 2021 Astellas Pharma Inc Earnings Release. Analysts on Wall Street expect Astellas Pharma will release earnings per share of $0.308. There is no recent news for this security. PR Newswire. Press releases. Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan. Financial Highlights; Financial Data (Annual Data) Financial Data (Quarterly Data) Sales of Major Products ; Revenue by Region; Annual Report; IR Library. Therapeutic Goods Administration AusPAR Betmiga mirabegron Astellas Pharma Australia Pty Ltd PM-2012-01928-3-3 Date of Finalisation 9 January 2014 Page 2 of 74 About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible … The Astellas Pharma Inc PE ratio based on its reported earnings over the past 12 months is 24.68.The shares are currently trading at ¥1849.5.. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sponsor: Astellas Pharma Australia Pty Ltd January 2014 . A high-level overview of Astellas Pharma Inc. (ALPMF) stock. ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer OSI is now a wholly-owned subsidiary of Astellas US Holding, Inc., a holding company owned by Astellas Pharma Inc., and OSI's common stock has ceased to … Investors. Thank you for visiting the Astellas Pharma Inc. Website. Wall Street analysts expect Astellas Pharma will release earnings per share of ¥30.25. Last Earnings Release: N/A; Next Ex-Dividend Date: N/A; Last Ex-Dividend Date: Sep. 28, 2020; Description: Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. Astellas Pharma (ALPMY) Recent Earnings. TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer … Replays of most recent earnings release conference calls; Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors) Corporate Governance information; About Astellas . On May 14, Astellas Pharma is presenting Q4 earnings. Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. There is no recent news for this security. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. This is an estimated date of earnings release. Astellas Pharma Completes Acquisition Of Iota Biosciences. Wall Street predict expect Astellas Pharma will release earnings per share of ¥22.35. News . Astellas Pharma (ALPMY) reported 3rd Quarter December 2020 earnings of $0.31 per share on revenue of $3.1 billion.. Astellas Pharma Inc and its subsidiaries are engaged in manufacturing, marketing and import/export of pharmaceuticals. Royalty income makes up a small percentage of Astellas' overall sales.
Super Guida Tv On Demand, Fritzchen Witze Von Früher, Abmahnung Filesharing Forum, Tavor Mit Alkohol, Travemünde Sehenswürdigkeiten Kinder, Fivem Unmarked Police Cars, Mobilheim Dauerhaft Mieten, Ping Verbessern Router,